Joint Venture2 Nov 2023, 02:55 pm
SPARC enters into exclusive license agreement for SCD-153
AI Summary
Sun Pharma Advanced Research Company Ltd. (SPARC) has entered into an exclusive worldwide license agreement for SCD-153 with Johns Hopkins University (JHU) and The Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences (IOCB) for the treatment of Alopecia Areata. The agreement includes upfront payment, milestone payments, and tiered royalties on sales. The licensing of SCD-153 marks another successful collaboration between SPARC and an academic institute under its outreach program with academia.,
Key Highlights
- First-in-class topical formulation for the treatment of Alopecia Areata
- IND approved by DCGI
- Exclusive worldwide license agreement with JHU and IOCB
- Upfront payment, milestone payments, and tiered royalties on sales